Floatz logo

Dc-Cik

Acute Lymphoblastic Leukemia, in Relapse

Beijing GoBroad HospitalCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Acute Lymphoblastic Leukemia, in Relapse cohort.

Asset / SponsorPhaseRating
Murine Autologous Anti-Cd19 Chimeric Antigen Receptor T Cells
Beijing Boren Hospital
Phase 2B
gsk1120212
Princess Maxima Center for Pediatric Oncology
Phase 1/2CCC
Carcik-Cd19
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Phase 1/2CCC
Nivolumab
Assistance Publique - Hôpitaux de Paris
Phase 1/2CC
Autologous Cd7 Car T-Cell
Beijing GoBroad Hospital
Phase 1/2CC

View all 18 →

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →